Find the funding your business is owed

Call for proposals aimed at accelerating the market launch of digital and AI-powered medical technologies.

European Union

€850Knon-repayable

Call for proposals aimed at accelerating the market launch of digital and AI-powered medical technologies. This initiative provides up to EUR 850,000 in funding for collaborative projects to bridge the gap between high-level prototypes and commercial availability. Specifically, the call targets solutions at Innovation Maturity Level (IML) 6 that are ready for pivotal clinical studies, regulatory submission, and the finalization of a robust commercial strategy. Selected projects are expected to deliver significant societal and economic value. To ensure long-term viability, innovations must be backed by a clear business model and robust Intellectual Property Rights. Furthermore, the EIT has set ambitious post-funding targets: Patient Reach: The potential to impact at least 150,000 EU citizens; Revenue Target: Achieving a minimum of €10,000 in revenue within three years of the project’s conclusion; and Accountability: Consortia must provide a comprehensive workplan and agree to long-term monitoring of their Key Performance Indicators (KPIs).

Call for proposals to fund collaborative projects that implement Value-Based Healthcare (VBHC) models.

European Union

€700Knon-repayable

Call for proposals to fund collaborative projects that implement Value-Based Healthcare (VBHC) models. This initiative is designed to bridge the gap between high-maturity, market-ready medical solutions and their formal adoption into real-world clinical practice. With awards of up to EUR 700,000, the program supports industry-led projects that demonstrate how digital and data-driven care pathways can improve patient outcomes while simultaneously enhancing the economic sustainability of healthcare systems. The funding covers activities for up to 24 months, focusing on the practical deployment of innovations rather than early-stage research. Projects are expected to move beyond technical development to achieve broad clinical validation and market readiness.

€1M – €10.6Mnon-repayable

Call for proposals to support civil protection and disaster risk management projects.

European Union

With a total budget of EUR 10.6 million, this call provides grants of up to EUR 1 million to strengthen disaster resilience and cooperation both within the Union Civil Protection Mechanism (UCPM) and with third-party partners. Eligible applicants include public or private legal entities, and selected projects are expected to be completed within an initial duration of 24 months. The call is organized around three primary pillars designed to enhance the Preparedness Union Strategy: Priority 1: Risk Awareness: Focuses on fostering a culture of prevention among the general public. This includes fighting disinformation, engaging volunteers, and ensuring that vulnerable groups have access to evidence-based risk information; Priority 2: Early Warning to Early Action: Aims to bridge the gap between forecasting institutions and decision-makers. Projects should improve public warning systems and leverage emerging technologies like Artificial Intelligence to ensure alerts lead to rapid, effective responses; and Priority 3: Institutional Capacity: Seeks to build robust civil protection systems by embedding a preparedness-by-design principle. This involves integrating lessons learned from past emergencies and facilitating the transfer of scientific innovation into operational planning. By funding these initiatives, the Commission intends to overcome the challenges posed by cross-border hazards—such as wildfires, floods, and pandemics—which occur regardless of national boundaries. Successful proposals must demonstrate a clear plan for enhancing interoperability between organizations and sectors, ultimately resulting in a more coordinated and technologically advanced disaster risk management framework across Europe.

Call for proposals to develop next-generation Smart and Multifunctional Textiles (SMT) designed to enhance soldier survivability against modern battlefield threats, specifically drone-based surveillance.

European Union

€20Mnon-repayable

Call for proposals to develop next-generation Smart and Multifunctional Textiles (SMT) designed to enhance soldier survivability against modern battlefield threats, specifically drone-based surveillance. As symmetric warfare returns to Europe, this initiative seeks to move beyond traditional uniforms by integrating innovative materials that can interact with their environment. The project aims to develop individual camouflage solutions that are both static and dynamic, protecting dismounted soldiers from high-precision sensors and unmanned aerial vehicles (UAVs) across diverse climates, including Arctic and tropical zones. A total of EUR 20,000,000 is available, with individual awards potentially covering the full amount. By harmonizing soldier system requirements across EU Member States, this effort aims to: Modernize Operational Capacity: Equip European forces with uniforms that regulate temperature and manage moisture in extreme environments; Foster Innovation: Stimulate the European textile and defense industries to create a fully independent supply chain for smart materials; and Increase Combat Effectiveness: Provide soldiers with a technological edge that allows them to operate undetected during both day and night operations, reducing the Union's strategic dependencies on external defense technologies.

Call for proposals to establish a coordinated European Research Area (ERA) policy action to accelerate the development, validation, and uptake of New Approach Methodologies (NAMs) in biomedical research and regulatory testing.

European Union

€2.9Mnon-repayable

Call for proposals to establish a coordinated European Research Area (ERA) policy action to accelerate the development, validation, and uptake of New Approach Methodologies (NAMs) in biomedical research and regulatory testing. This call provides a total of EUR 2.90 million to fund a single overarching proposal that will harmonize strategies across Member States and Associated Countries for the 2025–2027 period. The project must facilitate an EU-wide forum involving ministries, regulatory agencies, academia, and the pharmaceutical industry. The action is structured around four primary Working Groups (WGs): WG1 (Development & Infrastructure): Identifying priority biological areas and infrastructures to leverage scientific strengths across different regions; WG2 (Validation & Uptake): Defining criteria for regulatory acceptance and prioritizing mature NAMs for qualification by the MedTech and pharmaceutical sectors; WG3 (Education & Training): Mapping and developing high-quality training modules on NAMs and the 3Rs principles (Replacement, Reduction, and Refinement) in partnership with knowledge institutes; WG4 (Openness & Awareness): Promoting open access to protocols and negative research results to prevent unnecessary duplication of animal testing and increasing regulator confidence in non-animal methods.

€9M – €44.2Mnon-repayable

Call for proposals to accelerate the development of vaccine candidates for emerging and re-emerging viral threats.

European Union

Call for proposals to accelerate the development of vaccine candidates for emerging and re-emerging viral threats. With a total budget of EUR 44.20 million, individual grants are expected to range between EUR 9.00 and 11.00 million. This initiative aims to diversify the global R&D portfolio and strengthen the EU’s leadership in pandemic preparedness, particularly as climate change accelerates the risk of viral disease emergence. Applicants must focus their proposal on advancing existing vaccine candidates for one of the following specific viruses: Mammarenaviruses: Junin or Lassa; Hantaviruses: Andes, Hantaan, or Sin Nombre; Other Emerging Viruses: Hendra, Enterovirus D68, or Venezuelan equine encephalitis. Proposals must address: Characterization and In-vivo Testing: Finalizing in-vitro characterization and conducting in-vivo protection tests in animal models (including non-human primates if requested by regulators); GMP Manufacturing: Producing batches of the most promising candidates according to Good Manufacturing Practices (GMP); Clinical Safety: Executing first-in-human clinical safety studies that outline a clear regulatory pathway; as well as Inclusive Research: Analyzing immune response and efficacy with attention to critical factors such as sex, age, disability, and ethnicity. For instance, researchers should note that vaccine responses can vary across ethnic groups; some studies have indicated that certain populations, such as those of African descent, may show different antibody titer levels or adverse event profiles compared to Caucasian populations, necessitating diverse clinical trial recruitment.